An Open-Label, Parallel-Group, Phase 1 Study to Evaluate the Pharmacokinetics, Safety, and Tolerability of BIIB122 in Healthy Adult Japanese, Chinese, and Caucasian Participants
Latest Information Update: 16 Sep 2022
At a glance
- Drugs DNL-151 (Primary)
- Indications Parkinson's disease
- Focus Pharmacokinetics
- Sponsors Biogen
Most Recent Events
- 13 Sep 2022 Status changed from recruiting to completed.
- 24 Feb 2022 Status changed from not yet recruiting to recruiting.
- 10 Feb 2022 New trial record